Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;76(4):370-376.
doi: 10.1016/j.mjafi.2020.08.004. Epub 2020 Sep 2.

Favipiravir: A new and emerging antiviral option in COVID-19

Umang Agrawal  1 , Reyma Raju  2 , Zarir F Udwadia  3
Affiliations
Review

Favipiravir: A new and emerging antiviral option in COVID-19

Umang Agrawal et al. Med J Armed Forces India. 2020 Oct.

Abstract

With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.

Keywords: Antiviral drugs; COVID-19; Favipiravir; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors have none to declare.

Figures

Fig. 1
Fig. 1
Chemical structure of favipiravir.
Fig. 2
Fig. 2
Mechanism of action of favipiravir.
Fig. 3
Fig. 3
Figure depicting adverse effects of favipiravir (source: Fabiflu monograph).
See this image and copyright information in PMC

References

    1. Search of: favipiravir | Covid19 - list results - clinicaltrials.Gov. 2020. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=favipiravir&cnt... Clinicaltrials.gov. [online] Available at:
    1. Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013 Nov;100:446–454. - PMC - PubMed
    1. Toyama Chemicals. Summary of Product Characteristics of Avigan.
    1. Madelain V., Nguyen T.H., Olivo A. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 2016 Aug;55:907–923. doi: 10.1007/s40262-015-0364-1. - DOI - PMC - PubMed
    1. Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PloS One. 2013;8 - PMC - PubMed